Back to Market返回行情

CELZ Creative Medical Technology Holdings, Inc.

USHealthcare
$0.9413-5.87%ClosedMarket Cap: $2.4M

As of 2026-07-09 16:00

Why CELZ matters now

Creative Medical Technology Holdings, Inc. (CELZ) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.94 with -5.87% on the session and $2.4M in market capitalization; recent performance reads 1-month +1.83% and YTD +13.78%.

The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.4M, and EPS of $-0.38. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -97.1%.

The latest indexable market news headline is "Creative Medical Technology Holdings Issues Mid-Year Update" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

1.35

P/S

1918.29

EV/EBITDA

-0.01

DCF Value

$2.94

FCF Yield

-97.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

-3986.6%

Operating Margin

-198049.6%

Net Margin

-192066.3%

ROE

-88.5%

ROA

-89.5%

ROIC

-96.9%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$0.00$-1.4M$-0.38
Q4 2025$3.0K$-1.9M$-0.73
FY 2025$6.0K$-6.0M$-2.52
Q3 2025$0.00$-1.2M$-0.48

Analyst Ratings

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 0Buy: 1Hold: 0Sell: 0Strong Sell: 0

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.83

Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.